China's NEO Brain Chip Beats Neuralink to First Commercial BCI Sale
Abhishek Gautam13 min readQuick summary
Neuracle's epidural NEO implant cleared for patients with spinal cord injuries — sits on the dura mater, not in cortex. Neuralink N1 still experimental with 21 trial participants.
Read next
- China's 15th Five-Year Plan Mentions AI 50 Times and Chips Barely at All
- IEA Just Released 400 Million Barrels of Oil. It Did Not Work. Here Is What That Means for Tech.
China's National Medical Products Administration (NMPA) approved NEO — a coin-sized invasive brain-computer interface from Neuracle Technology and Tsinghua University researchers — for commercial use beyond clinical trials, making it the world's first invasive BCI cleared for sale, according to MIT Technology Review, Scientific American, and People's Daily reporting on the March 2026 decision that resurfaced globally in June 2026.
Neuralink, by contrast, remains in FDA-supervised human trials with 21 participants as of early 2026 — no US commercial approval yet.
What NEO Is — and Why Regulators Moved Faster
NEO is an epidural implant: eight sensors sit on the dura mater (the brain's protective membrane), not inside the cortex like Neuralink's N1 threads.
| Design choice | NEO (Neuracle) | Neuralink N1 |
|---|---|---|
| Placement | On dura mater — ~90 min surgery | Penetrates cortex |
| Risk profile | Lower hemorrhage / glial scarring risk | Higher invasiveness, signal degradation over time |
| Output | Brain signals → skull transmitter → PC → soft robotic glove | Direct neural read/write for cursor/device control |
| Approval | NMPA commercial (March 2026) | Clinical trials only (US) |
Avinash Singh (University of Technology Sydney), cited by MIT Technology Review, said the epidural path faces fewer regulatory constraints than penetrating designs — a plausible reason NEO reached market first despite Neuralink's global headlines.
Clinical Numbers — Not Just a Press Release
Per NMPA and Neuracle statements reported by Xinhua / People's Daily:
- 36 clinical procedures since October 2023
- 4 feasibility trials + 32 multi-center GCP trials (most in 2025)
- Patients showed varying grasp improvement; some neural remodeling signs
- Approved cohort: ages 18–60, limb paralysis from spinal cord injury, some residual arm function
Dong Hui, 39, paralyzed after a car accident, told MIT Technology Review he wrote his name again after 11 months of ~2.5-hour daily training — grabbing a ball on day nine without the glove was a breakthrough moment.
Our Analysis: Why Developers and Infra Teams Should Care
This is not sci-fi cosplay — it is medical device manufacturing + signal processing + rehab software at national scale.
1. China just created a commercial BCI category
Days after approval, China assigned NEO a health-insurance product code — the first step toward partial reimbursement in the state healthcare system. That is volume manufacturing, not lab demos — same pattern as China GPU/robotics five-year plan priorities.
2. "Race" framing is wrong — market definitions differ
Meicen Sun (University of Illinois), cited by MIT Technology Review: US wins on state-of-the-art performance; China wins on accessible scale. Nick Ramsey (Radboud University) warns against a simplistic US-China "endpoint" race — BCIs have no finish line yet.
3. Neuralink's consumer fantasy vs hospital reality
Musk has discussed healthy humans getting implants someday. NEO's approved label is spinal cord injury patients with specific arm function — hospital rollouts, not phone-adjacent consumer electronics.
4. Pipeline behind NEO
Beinao-1 (NeuCyber NeuroTech / Beijing brain institute) targets movement + speech for SCI and ALS — possible approval ~2028 per expert commentary. NeuroXess, StairMed, and others already in field trials.
5. Rare US-China collaboration lane
Axoft (Cambridge, MA) reportedly partners with a Shanghai hospital on BCI trials — neurotech is one of few sectors still doing cross-border human studies despite export tensions.
Developer angle: BCI stacks need low-latency signal decoding, on-device inference, rehab gamification, and HIPAA-grade logging — same talent pool as embodied AI / humanoid robots and Nvidia physical AI.
Key Takeaways
- March 2026 (NMPA): NEO = world's first invasive BCI approved for commercial sale beyond trials
- Neuracle + Tsinghua — coin-sized epidural implant on dura mater, not deep cortex penetration
- 36 trials since Oct 2023; patient Dong Hui regained writing after 11 months training
- Neuralink: 21 trial users, no US commercial approval; N1 penetrates cortex
- China policy: BCI listed in latest five-year plan alongside quantum + humanoids; insurance coding started
- For developers: commercial BCIs = medical software + signal ML + rehab UX — new regulated hardware category
- What to watch: Beinao-1 (~2028), US FDA path for Neuralink, cross-border trials like Axoft-Shanghai
Sources
FAQ
Frequently Asked Questions
Did China approve a brain chip before Neuralink?
Yes. China's NMPA approved Neuracle Technology's NEO brain-computer interface for commercial use in March 2026, the first invasive BCI cleared for sale beyond clinical trials globally. Neuralink remains in FDA-supervised human trials with about 21 participants and has no US commercial approval.
How is China's NEO brain chip different from Neuralink?
NEO sits on the dura mater, the brain's outer protective membrane, with eight sensors and a skull-mounted transmitter. Neuralink's N1 device penetrates the cortex with threads. Experts say NEO's epidural design is less invasive and faces fewer regulatory safety hurdles.
How many clinical trials did Neuracle run for NEO?
Neuracle conducted 36 clinical procedures using NEO since October 2023, including four feasibility trials and 32 multi-center GCP trials, with most of the GCP volume completed in 2025 according to MIT Technology Review and Chinese regulatory announcements.
Who can receive the NEO brain implant in China?
NMPA approved NEO for patients aged 18 to 60 with paralysis in all limbs due to spinal cord injury who still retain some residual function in their arms. It pairs with rehabilitation training and a soft robotic glove.
Why does China's brain chip approval matter for developers?
It shifts BCIs from lab research to reimbursed medical manufacturing at scale, creating demand for signal processing software, rehab apps, on-device ML, and regulated health data pipelines — a new neurotech category alongside robotics and physical AI.
Free Weekly Briefing
The AI & Dev Briefing
One honest email a week — what actually matters in AI and software engineering. No noise, no sponsored content. Read by developers across 30+ countries.
No spam. Unsubscribe anytime.
More on Biotechnology
All posts →China's 15th Five-Year Plan Mentions AI 50 Times and Chips Barely at All
China submitted its 15th Five-Year Plan to the National People's Congress on March 5, 2026. AI appears 50+ times. Semiconductors barely register. Washington's chip export strategy is targeting the wrong layer. Here is what developers and tech strategists need to understand.
IEA Just Released 400 Million Barrels of Oil. It Did Not Work. Here Is What That Means for Tech.
The IEA approved the largest emergency oil release in history after the Strait of Hormuz closed. Brent crude is still above $90. AWS data centers in UAE and Bahrain were hit by drones. Qatar's helium supply is offline, threatening chip fabs globally. Here is the full developer and infrastructure impact.
China's EUV Machine After the ASML Ban: How Close SMEE Actually Got
China's SMEE has a working DUV prototype and an active EUV program. If it succeeds, ASML export controls fail. Current status, timeline, and what it means for chip supply.
Inside China's AI Manhattan Project: Export Control Gaps and the Race to Build Sovereign AI
China is running the largest state-directed AI programme in history — often called its "AI Manhattan Project." But US and allied export controls have critical gaps. Here is how China is navigating restrictions, what the gaps are, and what this means for global AI competition.
Written by
Software Engineer based in Delhi, India. Writes about AI models, semiconductor supply chains, and tech geopolitics — covering the intersection of infrastructure and global events. 836+ posts cited by ChatGPT, Perplexity, and Gemini. Read in 164 countries.